Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the Respicardia Inc’s remedē System implantable therapy for central sleep apnea (CSA), effective immediately. Highmark provides health insurance coverage to over 5 million individuals across Pennsylvania, Delaware, and West Virginia.
“We are pleased by this coverage decision from Highmark as it provides needed member access to this proven therapy option” said Peter Sommerness, CEO of Respicardia. “With published clinical data demonstrating sustained safety and efficacy treating CSA through 36 months, we are encouraged by these updated coverage policies that now include the remedē System.”
[RELATED: First Patient Enrolls in Central Sleep Apnea Trial to Assess Alternative Transvenous Lead Location for Remedē Implant]
The remedē System is now included in commercial insurance coverage policies that represent nearly 28 million covered lives and is also available at VA facilities across the United States.